AVBP
ArriVent BioPharma, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.10B
P/E Ratio
—
EPS
$-4.32
Beta
0.86
52W High
$27.22
52W Low
$15.55
50-Day MA
$23.10
200-Day MA
$21.14
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. is a specialized biopharmaceutical company committed to advancing innovative therapies aimed at addressing unmet medical needs in oncology and autoimmune disorders. Leveraging proprietary technologies and a solid scientific foundation, the company is developing a diverse pipeline of potential treatment candidates designed to significantly improve patient outcomes. With a strategic emphasis on high-growth sectors within the biopharma industry, ArriVent presents a compelling investment opportunity for institutional investors seeking exposure to transformative healthcare advancements.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -58.90% |
| Return on Assets | -36.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.24 |
| Price-to-Book | 3.58 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $44.20M |
| Float | $27.72M |
| % Insiders | 2.92% |
| % Institutions | 96.46% |
Analyst Ratings
Consensus ($41.10 target)
11
BuyData last updated: 4/7/2026